CAJ | 학술논문

目的：观察养正消积胶囊对肝癌经动脉化疗栓塞（ TACE）后生活质量的影响。方法将原发性肝癌患者60例随机分为对照组和治疗组，其中对照组30例，只接受TACE；治疗组30例，给予TACE＋养正消积胶囊；疗程均为28 d。于术前、术后采用QOL核心量表（ QLQ-C30）评估，评估其中5个功能领域、3个主要症状领域和6个单项条目。结果治疗组剔除2例，对照组剔除3例，治疗组临床获益（CB）为89倐．3％（25/28），对照组临床获益（CB）为92．6％（25/27），差异无统计学意义（ P ＞0．05）。2组患者功能量表评分差异无统计学意义（ P ＞0．05）。治疗组在疲乏、恶心呕吐、疼痛、睡眠障碍、食欲减退、腹泻等评分与治疗前比较有明显改善（ P ＜0．05， P ＜0．01）。对照组仅疲乏、食欲减退较治疗前改善（ P ＜0．05）。对照组疲乏、恶心呕吐、疼痛、睡眠障碍、食欲减退、腹泻评分分别降低了7．83％、4．01％、2．78％、7．41％、7．41％、2．74％，治疗组分别降低了11．91％、5．07％、13．99％、15．47％、15．47％、9．53％，治疗组的改善较对照组更为明显（ P ＜0．05）。 TACE术后出现骨髓抑制，对照组WBC降低多于治疗组（ P ＜0．05），ALT、AST 2组比较差异亦有统计学意义（ P ＜0．05）。结论养正消积胶囊能显著提高肝癌患者TACE后的生活质量。
목적：관찰양정소적효낭대간암경동맥화료전새（ TACE）후생활질량적영향。방법장원발성간암환자60례수궤분위대조조화치료조，기중대조조30례，지접수TACE；치료조30례，급여TACE＋양정소적효낭；료정균위28 d。우술전、술후채용QOL핵심량표（ QLQ-C30）평고，평고기중5개공능영역、3개주요증상영역화6개단항조목。결과치료조척제2례，대조조척제3례，치료조림상획익（CB）위89숙．3％（25/28），대조조림상획익（CB）위92．6％（25/27），차이무통계학의의（ P ＞0．05）。2조환자공능량표평분차이무통계학의의（ P ＞0．05）。치료조재피핍、악심구토、동통、수면장애、식욕감퇴、복사등평분여치료전비교유명현개선（ P ＜0．05， P ＜0．01）。대조조부피핍、식욕감퇴교치료전개선（ P ＜0．05）。대조조피핍、악심구토、동통、수면장애、식욕감퇴、복사평분분별강저료7．83％、4．01％、2．78％、7．41％、7．41％、2．74％，치료조분별강저료11．91％、5．07％、13．99％、15．47％、15．47％、9．53％，치료조적개선교대조조경위명현（ P ＜0．05）。 TACE술후출현골수억제，대조조WBC강저다우치료조（ P ＜0．05），ALT、AST 2조비교차이역유통계학의의（ P ＜0．05）。결론양정소적효낭능현저제고간암환자TACE후적생활질량。
Objective To observe the effect of Yangzhengxiaoji capsule on quality of life in hepatocellular carcinoma (HCC) after transcatheter arterial chemoembolization (TACE).Methods 60 patients with primary liver cancer were random-ly divided into control group and the treatment group with 30 patients in each group , control group only accept TACE .In treat-ment group, patients received TACE +Yangzhengxiaoji capsule;treatment lasted 28 d.Preoperative and postoperative QOL using the core scale ( QLQ-C30) assesses five functional areas , three main symptoms areas and six individual entries .Rseults Two cases were removed in treatment group and control group excluded three cases ,treatment groups'clinic benefit ( CB) rate was 89.3%(25/28), the control group's CB rate was 92.6%(25/27), the difference was not statistically significant ( P >0.05).2 groups of patients function scores showed no significant difference ( P >0.05).In the treatment group, fatigue, nausea, vomiting, pain, sleep disorders, loss of appetite, diarrhea score significantly improved compared with before treat-ment ( P <0.05, P <0.01).In control group, only fatigue, loss of appetite were improvement than before treatment ( P <0.05).Control group's fatigue, nausea, vomiting,pain,sleep disorders, loss of appetite, diarrhea scores were decreased 7.83%,4.01 %2,.78%,7.41%,7.41%,2.74%,the treatment group decreased by 11.91%,5.07%, 13.99%,15.47%, 15.47%,9.53%,improvement in the treatment group was more significantly than the control group ( P <0.05).TACE post-operative bone marrow suppression , WBC lower than the control group treated group ( P <0.05), ALT, AST 2 group differ-ence was also statistically significant ( P <0.05).Conclusion Yangzhengxiaoji capsule can significantly improve quality of life in hepatocellular carcinoma after transcatheter arterial chemoembolization .